These data suggest that pirtobrutinib’s pharmacokinetic/pharmacodynamic profile during therapy was sufficient to result in initial mechanistic inhibition of BCR pathway in CLL cells with a decline in CCL3/CCL4 biomarkers among diverse BTK backgrounds. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.